不同剂量左氧氟沙星治疗利福平耐药肺结核的临床效果

doi:10.3760/cma.j.issn.1007-1245.2022.06.007

国际医药卫生导报 ›› 2022, Vol. 28 ›› Issue (6): 762-765.DOI: 10.3760/cma.j.issn.1007-1245.2022.06.007

不同剂量左氧氟沙星治疗利福平耐药肺结核的临床效果

韩章琴¹ 王同生²

¹信阳市第五人民医院呼吸结核科，信阳　464000；
²河南科技大学第一附属医院呼吸科，洛阳　471000

收稿日期:2021-09-29 出版日期:2022-03-15 发布日期:2022-04-15
通讯作者: 韩章琴，Email：anyang6546@163.com
基金资助:
2018河南医学科技攻关计划项目（201803146）

Clinical effects of different doses of levofloxacin in the treatment of rifampicin-resistant pulmonary tuberculosis

Han Zhangqin¹, Wang Tongsheng²

¹Respiratory Tuberculosis Department, Xinyang Fifth People's Hospital, Xinyang 464000, China;
²Respiratory Department, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang 471000, China

Received:2021-09-29 Online:2022-03-15 Published:2022-04-15
Contact: Han Zhangqin, Email: anyang6546@163.com
Supported by:
Henan Medical Science and Technology Key Project in 2018 (201803146)

摘要/Abstract

摘要： 目的　探讨高剂量和低剂量左氧氟沙星治疗利福平耐药肺结核的疗效。方法　选取2019年5月至2020年9月信阳市第五人民医院收治的利福平耐药肺结核患者90例，根据随机数字表法分为高剂量组和低剂量组，各45例。高剂量组男25例、女20例，年龄（42.16±5.05）岁，给予左氧氟沙星0.6 g/d；低剂量组男23例、女22例，年龄（43.27±5.12）岁，给予左氧氟沙星0.4 g/d。比较两组临床疗效、病灶吸收率、治疗后生命质量及不良反应发生情况。计量资料组间比较采用独立样本t检验，计数资料采用χ²检验。结果　高剂量组治疗有效率及病灶吸收率分别为95.56%（43/45）、91.11%（41/45），均高于低剂量组75.56%（34/45）、66.67%（30/45），差异均有统计学意义（χ²=7.283、8.073，均P<0.05）。高剂量组社会功能、物质生活、躯体功能、心理功能评分分别为（81.25±9.46）分、（81.82±9.39）分、（89.05±8.26）分、（88.03±9.96）分，均高于低剂量组（67.34±7.56）分、（64.31±7.42）分、（65.58±7.47）分、（61.81±7.63）分，差异均有统计学意义（均P<0.05）。两组肺结核患者不良反应发生率比较，差异无统计学意义（χ²=0.080，P=0.777）。结论　高剂量左氧氟沙星治疗利福平耐药肺结核的临床效果显著，可明显促进病灶吸收，提高患者生活质量，且无不良反应增加，具有较高安全性，值得临床进一步推广应用。

关键词: 不同剂量, 左氧氟沙星, 利福平耐药肺结核, 临床效果, 生活质量

Abstract:

Objective　To investigate the clinical effects of different doses of levofloxacin in the treatment of rifampicin-resistant pulmonary tuberculosis. Methods　A total of 90 patients with rifampicin-resistant pulmonary tuberculosis were selected from Xinyang Fifth People's Hospital from May 2019 to September 2020, and were divided into a high-dose group and a low-dose group according to the random number table method, with 45 cases in each group. In the high-dose group, there were 25 males and 20 females, aged (42.16±5.05) years, and they were given levofloxacin 0.6 g/d; in the low-dose group, there were 23 males and 22 females, aged (43.27±5.12) years, and they were given levofloxacin 0.4 g/d. The clinical efficacies, focal absorption rates, quality of life, incidences of adverse reactions of the two groups were compared. Independent sample t test was used for the measurement data, and χ² test was used for the count data. Results　The effective rate in the high-dose group [95.56% (43/45)] was higher than that in the low-dose group [75.56% (34/45)], with a statistically significant difference (χ²=7.283, P<0.05). The focal absorption rate in the high-dose group [91.11% (41/45)] was significantly higher than that in the low-dose group [66.67% (30/45)], with a statistically significant difference (χ²=8.073, P<0.05). The scores of social function, material life, physical function, and psychological function in the high-dose group were (81.25±9.46) points, (81.82±9.39) points, (89.05±8.26) points, and (88.03±9.96) points, which were significantly higher than those in the low-dose group [(67.34±7.56) points, (64.31±7.42) points, (65.58±7.47) points, and (61.81±7.63) points], with statistically significant differences (all P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (χ²=0.080, P=0.777). Conclusion　The clinical effect of high-dose of levofloxacin in the treatment of rifampicin-resistant pulmonary tuberculosis is significant, which can significantly promote the absorption of lesions and improve the patients' quality of life, without increasing adverse reactions, with high safety, worthy of further clinical application.

Key words: Different doses, Levofloxacin, Rifampicin-resistant pulmonary tuberculosis, Clinical effect, Quality of life

韩章琴, 王同生. 不同剂量左氧氟沙星治疗利福平耐药肺结核的临床效果[J]. 国际医药卫生导报, 2022, 28(6): 762-765.

Han Zhangqin, Wang Tongsheng. Clinical effects of different doses of levofloxacin in the treatment of rifampicin-resistant pulmonary tuberculosis[J]. International Medicine and Health Guidance News, 2022, 28(6): 762-765.

参考文献

[1] 金凤霞,金瑶,黄庆萍. 初治菌阳肺结核患者异烟肼和利福平原发耐药调查[J]. 临床肺科杂志,2017,22(5):792-794. DOI:10.3969/j.issn.1009-6663.2017.05.005.

[2] 李强,马丽萍,高孟秋.27例利福平依赖肺结核的临床特点及治疗结果分析[J].北京医学,2017,39(7):708-711. DOI:10.15932/j.0253-9713.2017.07.020.

[3] 徐凯悦,强翠欣,赵建宏. 细菌对利福平耐药机制研究进展[J]. 中国感染控制杂志,2017,16(2):186-190. DOI:10.3969/j.issn.1671-9638.2017.02.021.

[4] 朱云祥,沈垚文,武韬,等. 左氧氟沙星与盐酸氨溴索联合治疗对重症肺炎老年患者免疫功能、肺功能和血气指标的影响研究[J]. 湖南师范大学学报(医学版),2017,14(5):148-151. DOI:10.3969/j.issn.1673-016X.2017.05.046.

[5] 林丽莎.不同剂量左氧氟沙星治疗下呼吸道感染的有效性及安全性[J].临床合理用药杂志,2016,9(26):25-26. DOI:10.15887/j.cnki.13-1389/r.2016.26.014.

[6] 朱倬敏. 左氧氟沙星联合胸腺肽治疗老年初治肺结核疗效观察[J]. 国际医药卫生导报,2017,23(9):1426-1428. DOI:10.3760/cma.j.issn.1007-1245.2017.09.046.

[7] 李丽琼,江程澄. 清金化痰汤与左氧氟沙星联合治疗对克雷伯杆菌肺炎患者白细胞计数、C反应蛋白水平及免疫功能的影响[J]. 中国中医急症,2018,27(3):429-431,438. DOI:10.3969/j.issn.1004-745X.2018.03.015.

[8] 朱可辉. 左氧氟沙星与大剂量氨溴索联用对肺癌患者伴医院感染的临床疗效与安全性分析[J]. 抗感染药学,2016,13(3):612-614. DOI:10.3969/j.issn.1672-7878.2016. 03-047.

[9] 王茂军,马丙乾,郝俊玲,等. 不同方案治疗单耐异烟肼或利福平肺结核患者的预后分析[J]. 中国防痨杂志,2018,40(3):286-291. DOI:10.3969/j.issn.1000-6621.2018.03.014.

[10] 王新. 探析左氧氟沙星与莫西沙星治疗耐药性肺结核的疗效和安全性[J]. 中外医疗,2017,36(6):141-142,145. DOI:10.16662/j.cnki.1674-0742.2017.06.141.

[11] 范向阳,吴池,林武振,等. 不同剂量左氧氟沙星治疗耐药利福平肺结核患者的效果和安全性评价[J]. 结核病与肺部健康杂志,2016,5(2):118-120. DOI:10.3969/j.issn.2095- 3755.2016.02.012.

不同剂量左氧氟沙星治疗利福平耐药肺结核的临床效果

Clinical effects of different doses of levofloxacin in the treatment of rifampicin-resistant pulmonary tuberculosis

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 4

编辑推荐

Metrics

[1]	蒋佳, 周静怡, 纪小静, 胡小静. 基于扎根理论的干预措施应用于老年糖尿病患者中的效果观察[J]. 国际医药卫生导报, 2022, 28(5): 641-645.
[2]	许婉珠, 罗泽槟, 陈楚君, 王沛如, 洪丽纯. 癌症患者的出院准备度现状及影响因素分析[J]. 国际医药卫生导报, 2022, 28(5): 734-739.
[3]	吕文伟, 魏澎涛, 张寒, 康延杰, 杨凌博, 刘红燕, 尚亚峰, 孙建涛. 负压组合式输尿管镜与输尿管软镜钬激光碎石术治疗单侧上尿路结石的对比研究[J]. 国际医药卫生导报, 2021, 27(6): 871-874.
[4]	黄丁兰, 崔鑫浩, 许春华. 吞咽康复训练对脑卒中吞咽功能障碍患者吞咽功能和生活质量的影响[J]. 国际医药卫生导报, 2021, 27(6): 932-934.